Dr. Sandeep Soni, MD, is the Executive Director at CRISPR Therapeutics, Inc., a leading biotechnology company focused on developing transformative gene-based medicines for serious diseases. His extensive background in paediatric hematology, oncology, and stem cell transplantation has positioned him at the forefront of innovative therapies, particularly in the realm of gene editing.

Dr. Soni's academic journey includes training in multiple countries, including India, Israel, and the United States. He has played a pivotal role in advancing first-in-human gene therapy trials aimed at treating genetic disorders such as sickle cell disease and beta-thalassemia. His contributions to these fields have been instrumental in improving patient outcomes and expanding treatment options for rare blood disorders.

A significant aspect of Dr. Soni's work focuses on addressing health disparities among tribal and indigenous populations. His commitment to these communities is reflected in his research initiatives that aim to develop accessible gene therapies tailored to their unique genetic profiles. By collaborating with local health authorities and engaging with tribal leaders, he seeks to ensure that advancements in gene therapy benefit these underserved populations.

Dr. Soni's leadership at CRISPR Therapeutics also involves advocating for ethical practices in gene therapy development, particularly concerning vulnerable communities. He emphasises the importance of culturally sensitive approaches in clinical trials and healthcare delivery, aiming to build trust and ensure equitable access to cutting-edge treatments.

Through his dedication to both scientific innovation and public health, Dr. Sandeep Soni continues to make significant strides in improving health outcomes for diverse populations, particularly those historically marginalised within the healthcare system. His work not only advances the field of gene therapy but also champions the cause of health equity for indigenous peoples.